Alimera Sciences, Inc.

ALIM

US0162592028

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.49 ^USD	+5.44%		+4.49%	-19.21%

Mar. 25	Maxim Initiates Alimera Sciences at Buy Rating With $10 Price Target	MT
Mar. 19	Alimera Sciences, Inc. Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network	CI

Alimera Sciences, Inc. Provides Revenue Guidance for the Year 2024

March 07, 2024 at 07:30 am EST

Alimera Sciences, Inc. provided revenue guidance for the year 2024. For the year, the company expected to deliver over $105 million in net revenue.

Latest news about Alimera Sciences, Inc.

Maxim Initiates Alimera Sciences at Buy Rating With $10 Price Target	Mar. 25	MT
Alimera Sciences, Inc. Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network	Mar. 19	CI
Transcript : Alimera Sciences, Inc., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Alimera Sciences, Inc. Enters into the Seventh Amendment to Its Loan and Security Agreement	Mar. 07	CI
Earnings Flash (ALIM) ALIMERA SCIENCES Posts Q4 Revenue $26.3M	Mar. 07	MT
Earnings Flash (ALIM) ALIMERA SCIENCES Posts Q4 Revenue $26.3M	Mar. 07	MT
Alimera Sciences, Inc. Provides Revenue Guidance for the Year 2024	Mar. 07	CI
Alimera Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Alimera Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
North American Morning Briefing : Powell Still in -2-	Mar. 07	DJ
Alimera Completes Recruitment for the Synchronicity Study	Jan. 04	CI
Alimera Sciences Appoints New CFO	Jan. 02	MT
Alimera Sciences, Inc. Names Elliot Maltz as Chief Financial Officer	Jan. 02	CI
Alimera Sciences, Inc. Appoints Todd Wood as President of U.S. Operations	Dec. 12	CI
Alimera Sciences, Inc Appoints Maggie A. Pax to its Board of Directors	Nov. 08	CI
Alimera Announces Scientific Data Highlighting ILUVIEN to Be Presented at the American Academy of Ophthalmology	23-10-31	CI
Transcript : Alimera Sciences, Inc., Q3 2023 Earnings Call, Oct 26, 2023	23-10-26
Earnings Flash (ALIM) ALIMERA SCIENCES Reports Q3 Revenue $23.4M	23-10-26	MT
Alimera Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Alimera Sciences Names Jason Werner as COO	23-10-03	MT
Alimera Sciences, Inc. Announces Management Appointments	23-10-03	CI
Transcript : Alimera Sciences, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Earnings Flash (ALIM) ALIMERA SCIENCES Reports Q2 Revenue $17.5M	23-08-10	MT
Alimera Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
North American Morning Briefing : Attention Turns -2-	23-08-10	DJ

Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. ILUVIEN is an intravitreal implant that treats patients by delivering a continuous micro dose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. DME is also treated by laser photocoagulation, a retinal procedure in which a laser is used to apply a burn.

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Alimera Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.49 USD

Average target price

8 USD

Spread / Average Target

+129.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
ALIMERA SCIENCES, INC.	-19.21%	183M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals